» Articles » PMID: 21362373

Molecular Basis of Von Hippel-Lindau Syndrome in Chinese Patients

Overview
Specialty General Medicine
Date 2011 Mar 3
PMID 21362373
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Von Hippel-Lindau (VHL) syndrome is an autosomal dominant familial cancer syndrome predisposing the affected individuals to multiple tumours in various organs. The genetic basis of VHL in Southern Chinese is largely unknown. In this study, we characterized the mutation spectrum of VHL in nine unrelated Southern Chinese families.

Methods: Nine probands with clinical features of VHL, two symptomatic and eight asymptomatic family members were included in this study. Prenatal diagnosis was performed twice for one proband. Two probands had only isolated bilateral phaeochromocytoma. The VHL gene was screened for mutations by polymerase chain reaction, direct sequencing and multiplex ligation-dependent probe amplification (MLPA).

Results: The nine probands and the two symptomatic family members carried heterozygous germline mutations. Eight different VHL mutations were identified in the nine probands. One splicing mutation, NM_000551.2: c.463+1G > T, was novel. The other seven VHL mutations, c.233A > G [p.Asn78Ser], c.239G > T [p.Ser80Ile], c.319C > G [p.Arg107Gly], c.481C > T [p.Arg161X], c.482G > A [p.Arg161Gln], c.499C > T [p.Arg167Trp] and an exon 2 deletion, had been previously reported. Three asymptomatic family members were positive for the mutation and the other five tested negative. In prenatal diagnosis, the fetuses were positive for the mutation.

Conclusions: Genetic analysis could accurately confirm VHL syndrome in patients with isolated tumours such as sporadic phaeochromocytoma or epididymal papillary cystadenoma. Mutation detection in asymptomatic family members allows regular tumour surveillance and early intervention to improve their prognosis. DNA-based diagnosis can have an important impact on clinical management for VHL families.

Citing Articles

Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: not a needle in a haystack.

Castro-Teles J, Sousa-Pinto B, Rebelo S, Pignatelli D Endocr Connect. 2021; 10(11):R293-R304.

PMID: 34596579 PMC: 8630766. DOI: 10.1530/EC-21-0294.


Novel gene mutation in von Hippel-Lindau disease - a report of two cases.

Wang J, Cao W, Wang Z, Zhu H BMC Med Genet. 2019; 20(1):194.

PMID: 31823746 PMC: 6902464. DOI: 10.1186/s12881-019-0930-8.


Pedigree analysis, diagnosis and treatment in Von Hippel-Lindau syndrome: A report of three cases.

Wang Y, Liang G, Tian J, Wang X, Chen A, Liang T Oncol Lett. 2018; 15(4):4882-4890.

PMID: 29616089 PMC: 5876499. DOI: 10.3892/ol.2018.7957.


Clinical and genetic investigation of a multi-generational Chinese family afflicted with Von Hippel-Lindau disease.

Zhang J, Ma J, Du X, Wu D, Ai H, Bai J Chin Med J (Engl). 2015; 128(1):32-8.

PMID: 25563310 PMC: 4837816. DOI: 10.4103/0366-6999.147802.


Germline mutation of Glu70Lys is highly frequent in Korean patients with von Hippel-Lindau (VHL) disease.

Hwang S, Ku C, Lee J, Hur K, Lee M, Lee C J Hum Genet. 2014; 59(9):488-93.

PMID: 25078357 DOI: 10.1038/jhg.2014.61.